Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines
Nevro Corp (NYSE:NVRO) posted second-quarter revenue of $102.3 million, +81% Y/Y, missing the consensus of $107.7 million. Total U.S. permanent…
Mid-Morning Market Update: Markets Open Higher; Kellogg Tops Q2 Views
Following the market opening Thursday, the Dow traded up 0.49% to 34,961.76 while the NASDAQ rose 0.39% to 14,837.81. The S&P also rose, gaining 0.34% to 4,417.73.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
Morgan Stanley Maintains Overweight on Nevro, Lowers Price Target to $150
Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and lowers the price target from $199 to $150.
10 Biggest Price Target Changes For Thursday
Keybanc boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $697 to $711. HubSpot shares rose 1.1% to close at $590.00 on Wednesday.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Canaccord Genuity Downgrades Nevro to Hold, Announces $112 Price Target
Canaccord Genuity analyst William Plovanic downgrades Nevro (NYSE:NVRO) from Buy to Hold and announces $112 price target.
JMP Securities Maintains Market Outperform on Nevro, Lowers Price Target to $160
JMP Securities analyst David Turkaly maintains Nevro (NYSE:NVRO) with a Market Outperform and lowers the price target from $190 to $160.
Wells Fargo Downgrades Nevro to Equal-Weight, Announces $122 Price Target
Wells Fargo analyst Lawrence Biegelsen downgrades Nevro (NYSE:NVRO) from Overweight to Equal-Weight and announces $122 price target.